Novogen’s (KZIA) Buy Rating Reiterated at BTIG Research

BTIG Research reiterated their buy rating on shares of Novogen (NASDAQ:KZIA) in a research note published on Thursday,Benzinga reports. They currently have a $40.00 price objective on the stock.

Several other research analysts have also recently weighed in on the company. Canaccord Genuity Group began coverage on Novogen in a research report on Thursday, August 13th. They set a “buy” rating and a $29.00 price objective for the company. Lake Street Capital initiated coverage on Novogen in a research report on Thursday, June 11th. They issued a “buy” rating and a $32.00 target price on the stock. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Novogen in a research note on Friday, July 17th. Six equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $27.33.

Novogen Trading Up 1.6%

KZIA stock opened at $11.19 on Thursday. The stock has a 50-day moving average price of $13.11 and a two-hundred day moving average price of $11.68. Novogen has a 1 year low of $4.86 and a 1 year high of $17.40.

About Novogen

Novogen (NASDAQ:KZIA) is a clinical-stage biotechnology company focused on the discovery and development of novel small-molecule therapeutics for the treatment of cancer. The company’s pipeline includes GDC-0084, a brain-penetrant phosphoinositide 3-kinase (PI3K) inhibitor in Phase II development for glioblastoma, as well as Cantrixil, an orally bioavailable small molecule designed to target treatment-resistant ovarian cancer stem cells. Novogen’s research efforts leverage structure-based drug design to optimize selectivity and pharmacokinetic profiles, seeking to address high-unmet medical needs in oncology.

Founded in Australia and now headquartered in New York City, Novogen maintains research facilities in Perth and collaborates with academic institutions and contract research organizations worldwide.